The collaboration will combine AMD GPUs, CPUs and software with PsiQuantum’s photonics technology, targeting drug discovery and error correction.
PsiQuantum and AMD announced an expanded strategic partnership to co-design the computing infrastructure required to operate utility-scale, fault-tolerant quantum computers and the hybrid applications that combine quantum, high-performance, and AI computing.

The collaboration builds on the companies’ existing work around AMD Versal FPGA technology—selected by PsiQuantum for the development of its fault-tolerant quantum computing platform—and expands it into a broader relationship spanning AMD Instinct GPUs, AMD EPYC CPUs, and the AMD ROCm software stack, combined with PsiQuantum’s silicon photonics platform and its fully integrated platform. As quantum systems scale toward practical use, PsiQuantum and AMD expect the integration of classical high-performance, AI, and photonic quantum computing technology to form the world’s most powerful hybrid computing fabric.
To reinforce its commitment to the partnership, AMD also plans to make an equity investment into PsiQuantum.
The collaboration aligns with the U.S. Department of Energy’s recently released Quantum Genesis Priority Applications, which identify a key set of scientific problems that fault-tolerant quantum computers will be expected to solve.
PsiQuantum’s proprietary computational chemistry methodologies are performing beyond state-of-the-art calculations on AMD hardware today, and the companies’ planned initial focus on drug discovery falls within biological modeling, an identified emerging application area for Quantum Genesis.
By leveraging PsiQuantum’s expertise in workflow and fault-tolerant algorithm development, these methodologies help elevate today’s GPU-based approaches beyond state-of-the-art while preparing critical industries for the arrival of fault-tolerant quantum computing. Working with AMD, PsiQuantum researchers have optimized a highly accurate machine-learning decoder—PRISM—for low-latency implementation on programmable hardware accelerators. The result combines speed and accuracy in a design for real-time error correction in utility-scale photonic quantum computers.
The combination of PsiQuantum’s workflows with AMD’s GPU expertise running large scale simulation has already delivered initial breakthrough results in simulation of covalent inhibitors, a class of molecules relevant in drug discovery for oncology. PsiQuantum plans to build on these results and explore integrated accelerated computing solutions for commercial applications, initially focusing on the broader pharmaceutical research and drug discovery space.
Both companies will also explore expanding their collaboration with a footprint at the Illinois Quantum and Microelectronics Park (IQMP) in Chicago, America’s largest quantum computing project, where PsiQuantum serves as the anchor tenant.
AMD and PsiQuantum will share more about their strategic partnership at SC26 (November 15-20) in Chicago.
For more information about PsiQuantum, visit psiquantum.com.
For more information about AMD, visit amd.com.